Infectious Diseases in Child Care and School Settings

Total Page:16

File Type:pdf, Size:1020Kb

Infectious Diseases in Child Care and School Settings Infectious Diseases In Child Care and School Settings Guidelines for Child Care Providers and Health Consultants, School Nurses and Other Personnel Colorado Department of Public Health and Environment Communicable Disease Branch 4300 Cherry Creed Drive South Denver, Colorado 80246 P: 303-692-2700 | F: 303-782-0338 July 2019 Infectious Disease in Child Care and School Settings | 1 Acknowledgements These guidelines were compiled by the Communicable Disease Branch at the Colorado Department of Public Health and Environment. We would like to thank many subject matter experts at CDPHE for reviewing the document for content and accuracy. We would also like to acknowledge Donna Hite; Kate Lujan; Jillian Jaskunas; Theresa Rapstine; Deborah Monaghan; and Margaret Comstock for their comments and assistance in reviewing these guidelines. Special thanks to Heather Dryden, Administrative Assistant in the Communicable Disease Branch, for expert formatting assistance that makes this document readable. Revisions / Updates Date Description of Changes Pages/Sections Affected 2012 Major revision to content and format; combine previous separate Throughout guidance documents for child care and schools into one document Dec 2014 Updated web links due to CDPHE website change; updated several Throughout formatting issues; added hyperlinks to table of contents; no content changes May 2015 Added updated FERPA letter from the CO Dept. of Education; added Introduction links to additional info to the animal contact section in the introduction; added new bleach concentration disinfection guidance Oct 2015 Corrected reporting information for aseptic meningitis Aseptic Meningitis Jan 2016 Added information on animals in child care centers; updated bleach Introduction, various recommendations and EPA cleaners link; ensured that these guidelines sections are consistent with the new child care center regulations; updated reportable disease list; guidance on Clostridium difficile July 2019 Update content throughout; add guidance for parents/caregivers; add Throughout sections for tick borne illness and tularemia These guidelines are not a substitute for the School and Child Care Facility Health and Sanitation Regulations Child Care Regulations: https://www.colorado.gov/pacific/cdphe/child-care School Regulations: https://www.colorado.gov/pacific/cdphe/schools July 2019 Infectious Disease in Child Care and School Settings | 2 Table of Contents (alphabetically by disease name) Diseases in bold are conditions reportable to public health in Colorado. Any outbreak, regardless of etiology or setting, is reportable to public health. Diseases with an asterisk (*) are vaccine preventable diseases. Acknowledgements ......................................................................................................................... 2 Table of Contents (alphabetically by disease name) .................................................................................. 3 Diseases Grouped by Type of Spread .................................................................................................... 5 Introduction .................................................................................................................................. 7 Infectious Disease in Child Care and School Settings ............................................................................... 7 Public Health Reporting Requirements, Case Investigation, and Outbreak Investigation .................................... 7 Schools, Public Health Reporting, and FERPA ....................................................................................... 8 Communicable Reportable Conditions ................................................................................................... 9 Memo: Communicable Disease and Conditions Reportable by School Personnel ................................................ 11 Informing Parents/Guardians of Illness in the Facility ............................................................................ 14 Exclusion Guidelines for Children and Staff ......................................................................................... 14 Considerations for Developmentally Disabled or Immunocompromised Children ............................................. 15 Illness Transmission ..................................................................................................................... 15 Appropriate Antibiotic Use ............................................................................................................ 16 Disease Prevention: Hand Hygiene ................................................................................................... 17 Disease Prevention: Immunizations/Vaccines ...................................................................................... 18 Disease Prevention: Covering Coughs ................................................................................................ 18 Disease Prevention: Food Safety ...................................................................................................... 18 Disease Prevention: The Facility Environment ..................................................................................... 19 Animal Bites/Rabies ....................................................................................................................... 25 Bacterial Meningitis ........................................................................................................................ 27 Bedbugs ...................................................................................................................................... 29 Campylobacter ............................................................................................................................. 31 Chickenpox (Varicella) and Shingles (Herpes Zoster) ................................................................................ 33 Chlamydia ................................................................................................................................... 35 Clostridiodes Difficile (C. Difficile) ..................................................................................................... 36 Cytomegalovirus (CMV).................................................................................................................... 39 Common Cold ............................................................................................................................... 40 Croup ........................................................................................................................................ 42 Cryptosporidiosis ........................................................................................................................... 43 E. Coli O157 & Other Shiga Toxin-Producing Bacteria ............................................................................... 45 Fifth Disease (Human Parvovirus B19) .................................................................................................. 47 Genital Herpes (Herpes Simplex Virus (HSV)) ......................................................................................... 49 Genital Warts (Human Papillomavirus (HPV)) ......................................................................................... 50 Giardia ....................................................................................................................................... 51 Gonorrhea ................................................................................................................................... 53 Hand, Foot and Mouth Disease (HFM) ................................................................................................... 54 Head Lice (Pediculosis) ................................................................................................................... 56 Hepatitis A .................................................................................................................................. 58 Hepatitis B .................................................................................................................................. 60 Hepatitis C .................................................................................................................................. 62 Herpes (Cold Sores, Fever Blisters) ..................................................................................................... 63 HIV and AIDS ................................................................................................................................ 64 Impetigo ..................................................................................................................................... 65 July 2019 Infectious Disease in Child Care and School Settings | 3 Influenza .................................................................................................................................... 67 Measles ...................................................................................................................................... 69 Molluscum Contagiosum ................................................................................................................... 71 Mononucleosis .............................................................................................................................. 72 Methicillin-Resistant Staphylococcus Aureus (MRSA) & Staphylococcus Aureus .................................................
Recommended publications
  • Washington State Annual Communicable Disease Report 2008
    Washington State COMMUNICABLE DISEASE REPORT 2008 "The Department of Health works to protect and improve the health of people in Washington State." WASHINGTON STATE DEPARTMENT OF HEALTH Epidemiology, Health Statistics and Public Health Laboratories Communicable Disease Epidemiology Section 1610 NE 150th Street Shoreline, WA 98155 206-418-5500 or 1-877-539-4344 COMMUNICABLE DISEASE REPORT 2008 CONTRIBUTORS COMMUNICABLE DISEASE EPIDEMIOLOGY Rebecca Baer, MPH Katelin Bugler, MPH Mary Chadden Erin Chester, MPH Natasha Close, MPH Marisa D’Angeli, MD, MPH Chas DeBolt, RN, MPH Marcia Goldoft, MD, MPH Kathy Lofy, MD Kathryn MacDonald, PhD Nicola Marsden-Haug, MPH Judith May, RN, MPH Tracy Sandifer, MPH Phyllis Shoemaker, BA Deborah Todd, RN, MPH Sherryl Terletter Doreen Terao Wayne Turnberg, PhD, MSPH COMMUNITY AND FAMILY HEALTH Maria Courogen, MPH Kim Field, RN, MSN Salem Gugsa, MPH Tom Jaenicke, MPH, MBA, MES Shana Johnny, RN, MN Julieann Simon, MSPH i Mary Selecky Secretary of Health Maxine Hayes, MD, MPH Health Officer Dennis Dennis, PhD, RN Assistant Secretary Epidemiology, Health Statistics and Public Health Laboratories Judith May, RN, MPH Office Director for Communicable Disease Tony Marfin, MD, MPH, MA State Epidemiologist for Communicable Disease Romesh Gautom, PhD Director, Public Health Laboratories Juliet VanEenwyk, PhD, MS State Epidemiologist for Non-Infectious Disease This report represents Washington State communicable disease surveillance: the ongoing collection, analysis and dissemination of morbidity and mortality data to prevent
    [Show full text]
  • Eye Disease 1 Eye Disease
    Eye disease 1 Eye disease Eye disease Classification and external resources [1] MeSH D005128 This is a partial list of human eye diseases and disorders. The World Health Organisation publishes a classification of known diseases and injuries called the International Statistical Classification of Diseases and Related Health Problems or ICD-10. This list uses that classification. H00-H59 Diseases of the eye and adnexa H00-H06 Disorders of eyelid, lacrimal system and orbit • (H00.0) Hordeolum ("stye" or "sty") — a bacterial infection of sebaceous glands of eyelashes • (H00.1) Chalazion — a cyst in the eyelid (usually upper eyelid) • (H01.0) Blepharitis — inflammation of eyelids and eyelashes; characterized by white flaky skin near the eyelashes • (H02.0) Entropion and trichiasis • (H02.1) Ectropion • (H02.2) Lagophthalmos • (H02.3) Blepharochalasis • (H02.4) Ptosis • (H02.6) Xanthelasma of eyelid • (H03.0*) Parasitic infestation of eyelid in diseases classified elsewhere • Dermatitis of eyelid due to Demodex species ( B88.0+ ) • Parasitic infestation of eyelid in: • leishmaniasis ( B55.-+ ) • loiasis ( B74.3+ ) • onchocerciasis ( B73+ ) • phthiriasis ( B85.3+ ) • (H03.1*) Involvement of eyelid in other infectious diseases classified elsewhere • Involvement of eyelid in: • herpesviral (herpes simplex) infection ( B00.5+ ) • leprosy ( A30.-+ ) • molluscum contagiosum ( B08.1+ ) • tuberculosis ( A18.4+ ) • yaws ( A66.-+ ) • zoster ( B02.3+ ) • (H03.8*) Involvement of eyelid in other diseases classified elsewhere • Involvement of eyelid in impetigo
    [Show full text]
  • In the Prevention of Occupational Diseases 94 7.1 Introduction
    Report on the current situation in relation to occupational diseases' systems in EU Member States and EFTA/EEA countries, in particular relative to Commission Recommendation 2003/670/EC concerning the European Schedule of Occupational Diseases and gathering of data on relevant related aspects ‘Report on the current situation in relation to occupational diseases’ systems in EU Member States and EFTA/EEA countries, in particular relative to Commission Recommendation 2003/670/EC concerning the European Schedule of Occupational Diseases and gathering of data on relevant related aspects’ Table of Contents 1 Introduction 4 1.1 Foreword .................................................................................................... 4 1.2 The burden of occupational diseases ......................................................... 4 1.3 Recommendation 2003/670/EC .................................................................. 6 1.4 The EU context .......................................................................................... 9 1.5 Information notices on occupational diseases, a guide to diagnosis .................................................................................................. 11 1.6 Objectives of the project ........................................................................... 11 1.7 Methodology and sources ........................................................................ 12 1.8 Structure of the report .............................................................................. 15 2 Developments
    [Show full text]
  • Level I Syllabus
    LEVEL I SYLLABUS 1 ACDT Course Learning Objectives Upon Completion, Those Enrolled Will Be MODULE Prepared To... The Language of Dermatology 1. Define and spell the following cutaneous lesions/descriptors: a. Macule b. Patch c. Papule d. Nodule e. Cyst f. Plaque g. Wheal h. Vesicle i. Bulla j. Pustule k. Erosion l. Ulcer m. Atrophy n. Scaling o. Crusting p. Excoriations q. Fissures r. Lichenification s. Erythematous t. Violaceous u. Purpuric v. Hypo­/Hyperpigmented w. Linear x. Annular y. Nummular/Discoid z. Blaschkoid aa. Morbilliform bb. Polycyclic cc. Arcuate dd. Reticular Collecting & Documenting Patient History Part I 1. Describe the importance of documentation and chart review, while properly collecting dermatology­specific medical history components, including: a. Chief Complaint b. Past Medical History c. Family History d. Medications e. Allergies Collecting & Documenting Patient History Part II 1. Demonstrate the proper collection of dermatology­specific medical history and explain the significance of the following: a. Social History b. Review of Systems c. History of Present Illness Anatomy 1. Spell and document the following directional indicators while applying them to the appropriate anatomical landmarks: a. Proximal/Distal b. Superior/Mid/Inferior c. Anterior/Posterior d. Medial/Lateral e. Dorsal/Ventral 2. Spell and identify specific anatomical locations involving the: a. Scalp b. Forehead c. Ears d. Eyes e. Nose f. Cheeks g. Lips h. Chin i. Neck j. Back k. Upper extremity l. Hands m. Nails n. Chest o. Abdomen p. Buttocks q. Hips r. Lower extremity s. Feet Skin Structure and Function 1. Identify and spell the three primary layers of skin: a.
    [Show full text]
  • Mask Use in the Context of COVID-19 Interim Guidance 1 December 2020
    Mask use in the context of COVID-19 Interim guidance 1 December 2020 This document, which is an update of the guidance published patients wear the following types of mask/respirator in on 5 June 2020, includes new scientific evidence relevant to addition to other personal protective equipment that are the use of masks for reducing the spread of SARS-CoV-2, the part of standard, droplet and contact precautions: virus that causes COVID-19, and practical considerations. It ­ medical mask in the absence of aerosol contains updated evidence and guidance on the following: generating procedures (AGPs) • mask management; ­ respirator, N95 or FFP2 or FFP3 standards, or • SARS-CoV-2 transmission; equivalent in care settings for COVID-19 • masking in health facilities in areas with community, patients where AGPs are performed; these may cluster and sporadic transmission; be used by health workers when providing care • mask use by the public in areas with community and to COVID-19 patients in other settings if they cluster transmission; are widely available and if costs is not an issue. • alternatives to non-medical masks for the public; • In areas of known or suspected community or cluster • exhalation valves on respirators and non-medical masks; SARS-CoV-2 transmission WHO advises the following: • mask use during vigorous intensity physical activity; ­ universal masking for all persons (staff, patients, visitors, service providers and others) within the • essential parameters to be considered when health facility (including primary, secondary manufacturing non-medical masks (Annex). and tertiary care levels; outpatient care; and Key points long-term care facilities) ­ wearing of masks by inpatients when physical • The World Health Organization (WHO) advises the use distancing of at least 1 metre cannot be of masks as part of a comprehensive package of maintained or when patients are outside of their prevention and control measures to limit the spread of care areas.
    [Show full text]
  • Defining the Sizes of Airborne Particles That Mediate Influenza Transmission in Ferrets
    Defining the sizes of airborne particles that mediate influenza transmission in ferrets Jie Zhoua,1, Jianjian Weib,1, Ka-Tim Choya, Sin Fun Siaa, Dewi K. Rowlandsc, Dan Yua, Chung-Yi Wud, William G. Lindsleye, Benjamin J. Cowlinga, James McDevittf, Malik Peirisa,2, Yuguo Lib, and Hui-Ling Yena,2 aSchool of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China; bDepartment of Mechanical Engineering, The University of Hong Kong, Hong Kong SAR, China; cLaboratory Animal Services Centre, The Chinese University of Hong Kong, Hong Kong SAR, China; dGenomics Research Center, Academia Sinica, Taiwan, Republic of China; eAllergy and Clinical Immunology Branch, Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, WV 26505; and fDepartment of Environmental Health, Harvard School of Public Health, Boston, MA 02115 Contributed by Malik Peiris, January 16, 2018 (sent for review October 2, 2017; reviewed by Kanta Subbarao and Terrence M. Tumpey) Epidemics and pandemics of influenza are characterized by rapid ferrets via respiratory droplets, ferrets are often used to assess the global spread mediated by non-mutually exclusive transmission pandemic risk of zoonotic influenza viruses (11). However, the modes. The relative significance between contact, droplet, and conventional experimental settings cannot clarify the relative airborne transmission is yet to be defined, a knowledge gap for transmission efficiency of airborne particles of different sizes implementing evidence-based infection control measures. We that mediate droplet and airborne transmission. To address this devised a transmission chamber that separates virus-laden particles knowledge gap, we developed a transmission chamber capable by size and determined the particle sizes mediating transmission of separating influenza virus-laden particles into specific size of influenza among ferrets through the air.
    [Show full text]
  • Transmission of SARS-Cov-2: Implications for Infection Prevention Precautions
    Transmission of SARS-CoV-2: implications for infection prevention precautions Scientific brief 9 July 2020 This document is an update to the scientific brief published on 29 March 2020 entitled “Modes of transmission of virus causing COVID-19: implications for infection prevention and control (IPC) precaution recommendations” and includes new scientific evidence available on transmission of SARS-CoV-2, the virus that causes COVID-19. Overview This scientific brief provides an overview of the modes of transmission of SARS-CoV-2, what is known about when infected people transmit the virus, and the implications for infection prevention and control precautions within and outside health facilities. This scientific brief is not a systematic review. Rather, it reflects the consolidation of rapid reviews of publications in peer-reviewed journals and of non-peer-reviewed manuscripts on pre-print servers, undertaken by WHO and partners. Preprint findings should be interpreted with caution in the absence of peer review. This brief is also informed by several discussions via teleconferences with the WHO Health Emergencies Programme ad hoc Experts Advisory Panel for IPC Preparedness, Readiness and Response to COVID-19, the WHO ad hoc COVID-19 IPC Guidance Development Group (COVID-19 IPC GDG), and by review of external experts with relevant technical backgrounds. The overarching aim of the global Strategic Preparedness and Response Plan for COVID-19(1) is to control COVID-19 by suppressing transmission of the virus and preventing associated illness and death. Current evidence suggests that SARS-CoV-2, the virus that causes COVID-19, is predominantly spread from person-to-person.
    [Show full text]
  • Managing Communicable Diseases in Child Care Settings
    MANAGING COMMUNICABLE DISEASES IN CHILD CARE SETTINGS Prepared jointly by: Child Care Licensing Division Michigan Department of Licensing and Regulatory Affairs and Divisions of Communicable Disease & Immunization Michigan Department of Health and Human Services Ways to Keep Children and Adults Healthy It is very common for children and adults to become ill in a child care setting. There are a number of steps child care providers and staff can take to prevent or reduce the incidents of illness among children and adults in the child care setting. You can also refer to the publication Let’s Keep It Healthy – Policies and Procedures for a Safe and Healthy Environment. Hand Washing Hand washing is one of the most effective way to prevent the spread of illness. Hands should be washed frequently including after diapering, toileting, caring for an ill child, and coming into contact with bodily fluids (such as nose wiping), before feeding, eating and handling food, and at any time hands are soiled. Note: The use of disposable gloves during diapering does not eliminate the need for hand washing. The use of gloves is not required during diapering. However, if gloves are used, caregivers must still wash their hands after each diaper change. Instructions for effective hand washing are: 1. Wet hands under warm, running water. 2. Apply liquid soap. Antibacterial soap is not recommended. 3. Vigorously rub hands together for at least 20 seconds to lather all surfaces of the hands. Pay special attention to cleaning under fingernails and thumbs. 4. Thoroughly rinse hands under warm, running water. 5.
    [Show full text]
  • ICD-10 Will Allow Dermatologists to Effectively Communicate with Payors About Patient Visits
    ICD-10 UpDate ICD-10 Will Allow Dermatologists to Effectively Communicate With Payors About Patient Visits Angela J. Lamb, MD Practice Points With International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), derma- tologists will have a more accurate way to communicate with the pacopyyor. For example, physicians will be able to code for scabies as well as the cause of postscabetic pruritus. Physicians will have the option of coding for the reason the patient presented. For example, dermatolo- gists may code for a skin examination to screen for a malignant neoplasm. The reimbursement of the new codes has not been addressed; a head-to-head comparison will be needed during the testing period. not Do t is important that dermatologists do not over- The ICD-9 code 133.0 applies to scabies, and if we look the changes associated with the transition would like to code for the itch, we must enter a sec- Ito International Classification of Diseases, Tenth ond code for unspecified pruritic disorder (698.9).2 Revision, Clinical Modification (ICD-10-CM). Some With ICD-10-CM, we can be more specific and physicians believe that providing this level of speci- actually code for the cause of the itch. We will be ficity is not important because at the end of the day, able to mark the initial visit as B86 (scabies), but who is watching? You willCUTIS see with several of the subsequent visits for the itch related to scabies can codes highlighted in this column that specificity be coded as pruritus using the primary code L29.8 may be required before a claim can be submitted (other pruritus) and a new sequelae or late effect to the payor for processing.
    [Show full text]
  • ICD-10 International Statistical Classification of Diseases and Related Health Problems
    ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision Volume 2 Instruction manual 2010 Edition WHO Library Cataloguing-in-Publication Data International statistical classification of diseases and related health problems. - 10th revision, edition 2010. 3 v. Contents: v. 1. Tabular list – v. 2. Instruction manual – v. 3. Alphabetical index. 1.Diseases - classification. 2.Classification. 3.Manuals. I.World Health Organization. II.ICD-10. ISBN 978 92 4 154834 2 (NLM classification: WB 15) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]
  • Transmissibility and Transmission of Respiratory Viruses
    REVIEWS Transmissibility and transmission of respiratory viruses Nancy H. L. Leung Abstract | Human respiratory virus infections lead to a spectrum of respiratory symptoms and disease severity, contributing to substantial morbidity, mortality and economic losses worldwide, as seen in the COVID-19 pandemic. Belonging to diverse families, respiratory viruses differ in how easy they spread (transmissibility) and the mechanism (modes) of transmission. Transmissibility as estimated by the basic reproduction number (R0) or secondary attack rate is heterogeneous for the same virus. Respiratory viruses can be transmitted via four major modes of transmission: direct (physical) contact, indirect contact (fomite), (large) droplets and (fine) aerosols. We know little about the relative contribution of each mode to the transmission of a particular virus in different settings, and how its variation affects transmissibility and transmission dynamics. Discussion on the particle size threshold between droplets and aerosols and the importance of aerosol transmission for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and influenza virus is ongoing. Mechanistic evidence supports the efficacies of non-pharmaceutical interventions with regard to virus reduction; however, more data are needed on their effectiveness in reducing transmission. Understanding the relative contribution of different modes to transmission is crucial to inform the effectiveness of non-pharmaceutical interventions in the population. Intervening against multiple modes of transmission should be more effective than acting on a single mode. Human respiratory viruses include a broad range of supporting different modes of transmission will aid in viruses that infect cells of the respiratory tract, elicit the control of respiratory virus transmission. respiratory and other symptoms, and are transmitted Previous reviews and commentaries discussed the mainly by respiratory secretions of infected persons.
    [Show full text]
  • Diseases of the Canine Digit
    Diseases of the Canine Digit Diseases of the digit are relatively common and are particularly frustrating in terms of therapy. Unlike many other areas of skin, persisting diseases of the digit will almost always require biopsy to distinguish among a very long list of radically different etiologic possibilities. One cannot tell, just by looking at it, whether the digital swelling is chronic inflammation or squamous cell carcinoma, or whether the lump on the side of the digit is a harmless plasmacytoma or a potentially fatal amelanotic malignant melanoma. 1. Multiple nails that are brittle, deformed, or fall out: Most textbooks will provide a very long list of diseases of the nail and nail bed, but in practical terms I see only one syndrome: lupoid onychodystrophy. Bacterial and fungal paronychia, for example, is so rare in my collection that I have some skepticism that it even exists! The syndrome of lupoid onychodystrophy is seen in young mature dogs (1-5 years), and these animals present with a complaint of deformed nails that are periodically lost. The disease affects multiple digits on multiple feet, often eventually affecting all nails on all feet. The lesion is a lupus-like destructive disease (lymphocytic interface dermatitis with single cell necrosis) of the basal cells of the nail bed epithelium. As is true with similar histologic reactions affecting the nasal planum, gingiva, or conjunctiva, it is not yet clear whether this highly repeatable histologic pattern is really a reflection of a single disease, or is simply the way that the nail bed epithelium responds to a variety of different injuries.
    [Show full text]